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Intrinsic Sympathomimetic Activity and the Effects of Beta-Adrenergic
Blocking Drugs on Vulnerability to Ventricular Fibrillation
ERNST A. RAEDER , MD, RICHARD L. VERRIER, PhD, FACC, BERNARD LOWN, MD, FACC
Boston, Massachusetts
Beta-adrenergic blocking agents differ considerably in
their effects on myocardial excitable properties. The pos-
sibility that intrinsic sympathomimetic activity might
contribute to such differences has not been adequately
explored. This study examined the influence of intrinsic
sympathomimetic activity on the electrophysiologic ef-
fects of three agents with vary ing degrees of such activ-
ity. Intravenous propranolol (0.5 mglkg), oxprenolol (0.5
mg/kg) and pind olol (0.05 mglkg) were administered in
16 anesthetized dogs. The effects of the drugs on ven-
tr icular vulnerability were studied over a 2 hour period.
A growing number of beta-ad renocep tor blocking drugs are
becoming avai lable for the treatment of cardiac arrhythmias
(1-5) . Whereas some of these age nts have been demon-
strated to reduce myocard ial infarction and prevent sudden
ca rdiac death , the mechani sm for these actions remains un-
defined (2- 5). Individual agents, however, differ con sid-
era bly with regard to their card ioselectivity, extra-adren-
ergic effects and intrinsic sympathomimetic activity (6-8) .
The latter is of particular importance in light of experimental
and clinical evidence strongly implicating sympathetic neural
traffic in the ge nesis of life-threaten ing arrhythmias (9- 11).
The deg ree to which part ial ago nist activ ity of beta-adren-
ergic blocki ng drugs modul ates their antifibrillatory influ-
ence remains to be defined.
The objectives of the present study were to: I) examine
the effects of beta-adrenergic block ing agen ts with differin g
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Propranolol and oxprenolol raised the ventr icular fi-
brillation threshold by 42 and 56%, respectively. In con-
tra st , pindolol resulted in an elevation of only 25%. After
depletion of endogenous norepinephrine stores using re-
serpine, pindolol led to a decrease of the ventricular
fibrillation threshold, which was reversed by proprano-
lol. These data indicate that intrinsic sympathomimetic
activity of beta-adrenergic blocking agents substantially
alters their ultimate effect on myocardial excitable
properties.
degrees of parti al agonist activity on vulnerability to ven-
tricular fibrillation, and 2) exp lore the ro le of intr insic sym-
pathom imetic activ ity in ca techolamine-depleted animals.
Methods
Experimental preparation. The investigations we re
carried out in 16 healthy adult mongrel dogs of either sex
weighin g between 8 and 22 kg. The animals were anesthe-
tized with intravenous alpha-chloralose (100 mg/kg , 10%
weig ht in vo lume) and additional doses of 50 rng/kg were
given as required to maintain a consta nt level of anes thes ia .
Ventilation with a mixt ure of room air and 100% oxygen
was mai ntained by a cuffed endotrac hea l tube attached to a
Harvard respirator which was adj usted to keep arterial pH
between 7.35 and 7 .50 and parti al press ure of oxygen (Po 2)
at greater than 90 mm Hg. A femora l artery and vein were
cannulated with a polyeth ylene ca theter for arter ial blood
. sampling, blood pressure monitoring and drug administration.
Cardiac Testing
Electr ica l stimulation. Electrical stim ulatio n was ac-
com plished through an intracavitary electrode sys tem con-
sisting of a transvenous bipolar pac ing catheter (Medtronic
no . 58 19 platinum electrodes with an interelectrode distance
0735-1097/83/060 1442-5$03.00
BETA BLOCKERS AND VENTRICULAR FIBRILLATION J AM CaLL CARDIOL
1983.1(6) 1442-6
1443
of 1.5 em and a width of 3 mm) and an electrographic
recording catheter (4F semifloating bipolar temporary pac-
ing catheter; USCI). The recording catheter was bound to
the pacing catheter with silk ligatures, approximately 3 cm
proximal to the tip of the latter, and positioned at the right
ventricular apex by way of a jugular vein. The current was
set at twice the value of the mid-diastolic threshold. The
distal pole of the pacemaker catheter was made cathodal
with reference to the proximal pole. Heart rate was main-
tained constant at 210 beats/min by right ventricular pacing
during all determinations. Testing impulses were generated
by a constant current Grass S 44 square wave pulse generator
(Grass Instrument Company) in conjunction with an opti-
cally isolated constant current source of our own manufac-
ture. The constant current source used voltage-controlled
voltage-source circuitry to generate constant current pulses
directly proportional to the voltage input pulses. The output
of the device has a voltage compliance of 300 V direct
current. Current output of the optically isolated constant
current source can be verified by taking the voltage across
a variety of dummy load resistors (10 0 to 10 kO) and
employing Ohm's law. Current output, under actual oper-
ating conditions, can be verified by taking the voltage across
a small resistor (approximately 10 0) with an oscilloscope
equipped with a differential input amplifier and again using
Ohm's law. The timing of stimuli was controlled by a digital
timer with a crystal-controlled time base having an accuracy
of ± 0.01 % or better. Timing synchronization was from
the pacemaker stimulus. The stimulation system is equipped
with appropriate circuitry to inhibit the output of the pace-
maker from I to 5 seconds after delivery of the test stimulus.
The test stimuli were delivered after every 10th to 15th paced
beat.
Determination of ventricular fibrillation thresholds,
mid-diastolic thresholds and the effective refractory pe-
riod. Ventricular fibrillation thresholds were determined by
scanning electrical diastole in 5 ms intervals with constant
current cathodal pulses of 5 ms duration. Scanning began
at the boundary of the effective refractory period and ter-
minated beyond the T wave. The current was increased in
2 rnA steps until ventricular fibrillation occurred. The lowest
stimulus strength necessary to elicit ventricular fibrillation
defined the ventricular fibrillation threshold. Defibrillation
was accomplished within 5 seconds by a direct current 200
to 300 W-s discharge from a Lown cardioverter and deliv-
ered through a pair of copper plates previously fastened to
the thorax.
The excitable properties of the heart were determined by
setting a test stimulus of 0.1 rnA intensity and 2 ms duration
in mid-diastole and increasing stimulus intensity in 0.1 rnA
steps until a propagated response was evoked. The minimal
current required to elicit this response defined the diastolic
threshold.
The refractory period was determined by scanning the
RR interval with a test impulse of 2 ms duration and 3, 5
and 7 rnA intensity. The longest R to stimulus interval that
did not result in a propagated response marked the refractory
period.
Between defibrillations and isoproterenol tests, the ani-
mals were allowed to recover for at least 5 minutes to avoid
undue adrenergic influences.
Experimental Interventions
Oxprenolol, propranolol and pindolol were selected for
two reasons. First, the dose necessary to elicit beta-adren-
ergic blockade is well below the membrane-stabilizing dose.
Second, these agents differ considerably in their intrinsic
beta-stimulating properties (1,7,8,12,13). Specifically, pin-
dolol exerts strong beta-agonist effects, whereas oxprenolol
has only mild intrinsic sympathomimetic activity. Propran-
olol is devoid of beta-agonist effects.
Oxprenolol. This group comprised nine dogs that were
given oxprenolol, 0.5 mg/kg body weight intravenously.
Electrophysiologic determinations were initiated 20, 40,60,
80, 100 and 120 minutes after drug administration. At 30,
50, 70, 90 and 110 minutes, the effectiveness of beta-re-
ceptor blockade was tested by measuring peak increment in
heart rate and peak decrement in arterial blood pressure after
a bolus injection of isoproterenol, I jLg/kg.
Propranolol. The effects of propranolol, 0.5 mg/kg, were
studied in seven dogs. Three of these animals also underwent
testing with oxprenolol on the preceding day and four on
the following day. The study protocol was the same as for
oxprenolol.
Pindolol. In a group of seven dogs, we examined the
electrophysiologic effects of pindolol, 0.05 mg/kg. This
investigation was carried out in two steps. On day I, the
action of pindolol was studied adhering to the same protocol
for oxprenolol and propranolol. The second part of the in-
vestigation was designed to expose the intrinsic sympatho-
mimetic activity of pindolol by pretreating the dogs with
reserpine, 0.3 mg/kg intramuscularly, which has been shown
to deplete endogenous catecholamine stores (14). After 24
hours, the electrophysiologic studies were repeated at 20,
40, 60 and 80 minutes after administration of pindolol. The
degree of beta-adrenergic blockade was determined at 30,
50 and 70 minutes as described. In four dogs, we attempted
to block the sympathomimetic activity of pindolol by admin-
istration of propranolol, 0.5 mg/kg, 90 minutes after the
animals had received pindolol. The measurements were then
repeated.
Statistical analysis. The data were analyzed by analysis
of covariance on an IBM 4341 computer using a General
Linear Models Procedure (Statistical Analysis System). Dif-
ferences between drugs were estimated by computation of
the least square (LS) means and the probability values for
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Figure 2. Effects of the beta-adrenergic blocking drugs on the
mid-diastolic threshold. The interrupted line in this and suc-
ceeding figures represents pindolol at a dose of 0.5 mg/kg.
The peak prolongation of the refractory period achieved by
oxprenolol was 7 ± 5%, as determined using a 3 rnA
stimulus intensity.
Ventricular fibrillation threshold . The vulnerableperiod
threshold was significantly elevated by all three drugs (ox-
prenolol +56 ± 26%; propranolol + 42 ± 15% and pin-
dolol +25 ± 8%). However, the effect of pindolol was
less than that of oxprenolol (p < 0.004; Fig. 4), and the
difference between propranolol and pindolol failed to achieve
significance (p = 0.115).
Effects on myocardial excitable properties in cate-
cholamine-depleted dogs. In fivedogs, reserpine, 0.3 mgt
kg intramuscularly, was administered to depleteendogenous
catecholamine stores in order to evaluate the effect of pin-
dolo!'s intrinsic sympathomimetic activity on vulnerability.
The drug increased the mid-diastolic threshold by 20 ±
13% and shortened the refractory period duration by 10 ±
2%. The threshold for ventricular fibrillation was lowered
by 43 ± 10%. In four reserpinized dogs, propranolol, 0.5
160120
< 0.02 VI. Control
pc 0.025 VI. Control
~-::;:::I~'"
8040
100the null hypothesis (H") (LS mean [I] = LS mean [J]).
Data were normalized to percent change from control and
are reported as mean ± standard error of the mean.
Results
Suppression of isoproterenol-induced tachycardia.
All drugs achieved a comparable peak reduction in heart
rate response 30 minutes after test injections of isoproter-
enol, I J,Lg/kg. Oxprenolol reduced the tachycardia and hy-
potension by 78 and 80%, respectively. Similarresults were
obtained using propranolol and pindolol (Fig. I). The beta-
adrenergic blocking action of oxprenolol and propranolol
graduallysubsided over the course of the experiment, while
that of pindolol persisted after 90 minutes.
Effects on myocardial excitable properties in normal
animals. Mid-diastolic threshold. Oxprenolol raised the
excitability threshold to 43 ± 10%(probability [p] < 0.03)
and propranolol to 41 ± 8% (p < 0.02) above the control
value. Pindolol elevated the mid-diastolic threshold by 57
± 15% (p < 0.02), a value significantly different from that
induced by the other two agents (Fig. 2).
Effective refractory period. Administration of oxpren-
0101 and propranolol resulted in a comparableand significant
prolongation of ventricular refractoriness (8 ± 3 and 10 ±
2%, respectively; p < 0.001 versus control). By contrast,
pindolol shortened the refractory period duration by 4 ±
1% (p = 0.01; Fig. 3).
The maximal change of ventricular refractoriness indi-
cated was obtained at stimulus intensities of 3 rnA (pro-
pranolol and pindolol) and 5 rnA (oxprenolol). However,
statistical analysis of differences between the drugs was
performed separately for each of the stimulus intensities
employed. At 3, 5 and 7 rnA, the difference between the
effects of oxprenolol and propranolol on the one hand and
pindolol on the other was highly significant (p < 0.0001).
Figure1. Peak inhibition of isoproterenol-induced tachycardia by
oxprenolol, propranolol and pindolol in 16 normal dogs. The re-
sults indicate that these drugs produce comparable levels of beta-
receptor blockade.
Figure3. Influence of the beta-adrenergic blocking agents on the
effective refractory period of thecanine ventricle.
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Figure 4. Differential effect of oxprenolol, propranolol and pin-
dolol on the ventricular fibrillation (VF) threshold.
rug/kg, was injected subsequently. All the electrophysio-
logic changes elicited by pindolol were reversed (Fig. 5).
Dlscussion
This study examined the effects of diverse beta-receptor
blocking agents administered in doses to achieve compa-
rable degrees of beta-adrenergic blockade on myocardial
excitableproperties. Our results indicatethat thedrugsdiffer
considerably in their electrophysiologic actions. Specifi-
cally, propranolol and oxprenolol prolong the effective re-
fractory period, diminish cardiac excitability and raise the
threshold for ventricular fibrillation. In contrast, pindolol
shortens the duration of ventricular refractoriness and ele-
vates the mid-diastolicthreshold. Most notably, these agents
differ in their effects on the ventricularfibrillation threshold.
In particular, propranolol and oxprenolol exert a greater
action on this electrophysiologic property than does pindolol.
Mechanisms. What, then, is the basis for these diverse
electrophysiologic effects? Althoughall the drugs employed
in this study are known to exert membrane effects, extra-
adrenergic mechanisms such as membrane stabilization are
an unlikely cause because the doses required to produce
membrane stabilization are considerably greater than those
we administered. Specifically, the concentration of pro-
pranolol required for producing membrane effects is 50 to
100 times higher than that associated with inhibition of
exercise- or isoproterenol-induced tachycardia(15-18). The
membrane-stabilizing activity of oxprenolol is approxi-
mately half that of propranolol (19). Pindolol also exerts a
relatively minor influence on membrane stability (20).
A second possible mechanism that may account for the
differing antifibrillatory actionsof the drugsrelates to their
partialagonistactivity. To explorethis question, wefocused
on pindolol, which possesses substantial intrinsic sympa-
thomimetic activity. In catecholamine-depleted dogs, pin-
dolol decreased rather than increased the ventricular fibril-
TIME (minutll8)
Figure5. Influence ofpindolol ontheventricular fibrillation (VF)
threshold in five catecholamine-depleted dogs. Note that propran-
olol reversed the pindolol-induced decrease in the fibrillation
thresholds.
lation threshold and produced further shorteningrather than
prolongation of the refractory period. The pindolol-induced
reduction in the ventricular fibrillation threshold was abol-
ished by subsequent beta-adrenergic receptor blockade with
propranolol. These observations suggest that intrinsic sym-
pathomimetic activity has an adverse effect on pindolol's
overall influence on ventricular vulnerability.
Clinical implications. Our study demonstrates signifi-
cant differences in the effects of beta-receptor blockers on
the excitable properties of the heart. This effect relates, at
least in part, to an influence of intrinsic sympathomimetic
activity, which is contingent on the prevailing level of ad-
renergic tone. This is most evident under conditions of low
sympathetic tone.
Our results indicate that intrinsic sympathomimetic ac-
tivity may significantly alter the antifibrillatory influence of
beta-adrenergic blocking agents. It remains unknown, how-
ever, whether this principle also applies to patients at risk
for sudden cardiac death. Further clinical studies will be
required to answer this question which carries important
therapeutic implications .
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